abstract |
The present invention relates to a series of tricyclic compounds and their use as agonists of the sphingosine-1-phosphate subtype 1 (S1P1) receptor. Specifically, it relates to a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof. |